Expert Interview
Examining the recent data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) presented at the 2024 EASL Congress
Ticker(s): MDGLInstitution: Yale University
- Academic hepatologist, Associate Professor of Medicine (Digestive Diseases) and Director, Yale Viral Hepatitis Program.
- Treats patients with chronic liver diseases including the entire spectrum from cirrhosis, liver failure, and post-transplant; Approximately 5-10% of his patients have chronic pruritus symptoms, 200 patients with biopsy-proven NASH and a larger cohort of NAFLD, and 70 patients with PBC/PSC.
- Has served on the national steering committees for large observational cohort studies for liver disease and has published over 100 papers in the area of GI and liver diseases.
The MAESTRO-NASH study utilized an AI-based analysis to assess biopsy data. Can you explain how this AI-driven approach enhances our understanding of Rezdiffra's impact on fibrosis and its predictive value for progression to decompensated cirrhosis?
Added By: slingshot_insightsNoninvasive test data over three years showed that 91% of patients achieved improvement or stabilization of liver stiffness with Rezdiffra. How does this durability compare to other treatments for NASH, and what implications does it have for long-term patient management?
Added By: slingshot_insightsRezdiffra has shown improvements in health-related quality of life for patients with NASH. Can you discuss the importance of these findings, particularly in the domains of patient worry, health distress, and stigma, and how they influence overall treatment outcomes?
Added By: slingshot_insightsThe MAESTRO-NASH study included an analysis of patients with metabolic dysfunction and alcohol-associated liver disease (MetALD). What are the key findings from this subgroup, and how do they compare to the overall NASH population in terms of fibrosis improvement and steatohepatitis resolution?
Rezdiffra achieved significant improvements in fibrosis and NASH resolution at week 52. What mechanisms might explain Rezdiffra's ability to improve fibrosis, and how does this compare to other therapeutic approaches currently under investigation?
Added By: slingshot_insightsThe study identified 30 fibrotic features predictive of progression to cirrhosis using the SteatoSITE database. How critical is the integration of such biomarkers in developing personalized treatment plans for NASH patients?
Added By: slingshot_insightsPatients in the MAESTRO-NASH trial continue on therapy for up to 54 months. What are the expectations for long-term efficacy and safety from this extended follow-up, and how might these results impact the future approval and use of Rezdiffra?
Added By: slingshot_insightsGiven the promising results from the MAESTRO-NASH Phase 3 study, what steps are necessary to integrate Rezdiffra into standard clinical practice for treating NASH? What challenges might clinicians face in adopting this new treatment?
Added By: slingshot_insightsAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
